290
Participants
Start Date
July 31, 2016
Primary Completion Date
September 30, 2028
Study Completion Date
February 28, 2029
Alpha-1 MP
Alpha-1 MP 60 mg/kg/week for up to 104 weeks
St Vincent's Hospital Sydney, Darlinghurst
NZ Respiratory and Sleep Institute, Auckland
Gentofte Hospital, Hellerup
St Vincent's Hospital Melbourne, Fitzroy
Waikato Hospital, Hamilton
The Prince Charles Hospital, Chermside
Royal Adelaide Hospital, Adelaide
Institute for Respiratory Health Inc, Nedlands
Arhus Universitetshospital, Arhus C
Christchurch Hospital NZ, Christchurch
Karolinska Trial Allicance, KTA Prim, Stockholm
North Estonia Medical Centre Foundation, Tallinn
Skånes Universitetssjukhus, Malmö, Malmo
Turun yliopistollinen keskussairaala, Turku
Accellacare, Wilmington
Medical University of South Carolina, Charleston
University Of Miami Hospital, Doctors Office West Building, Miami
CHU Lyon - Hôpital Cardio-Vasculaire et Pneumologique Louis Pradel, Bron
University of Texas Health Center at Tyler, Tyler
St. Joseph's Hospital and Medical Center, Phoenix
Oregon Health & Science University, Portland
SBEI HPE Altai State Medical University of MoH and SD, Barnaul
Queen Elizabeth II Health Sciences Centre, Halifax
Inspiration Research Limited, Toronto
SPZOZ Szpital Uniwersytecki w Krakowie, Krakow
Instytut Gruzlicy i Chorob Pluc w Warszawie, Warsaw
Sahlgrenska Sjukhuset, Gothenburg
Lead Sponsor
Grifols Therapeutics LLC
INDUSTRY